UK Industry Urges Quick Adoption Of Accelerated Access Proposals As Brexit Clouds Gather
UK review proposes key changes to the way that new medicines and medical technologies are identified, developed and adopted for use in the National Health Service, including an Accelerated Access Partnership of stakeholders that will manage the accelerated pathway to patients, a new government unit to discuss commercial arrangements, and a “transformative designation” to flag up products of greatest interest.
You may also be interested in...
Government proposals to provide a boost for the UK’s industrial base to counter the disruption likely from Brexit include “sector deals” between companies and government, new funds for innovation, and encouraging later-stage venture capital financing, all of which are likely already on the wish-list of companies in the life sciences sector.
As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.